When Washington, D.C. officials’ efforts to slow the spread of HIV down stalled, it led to a rise in other STI diagnosis – to record highs even.
In 2015, during the first year of office for Mayor Muriel E. Bowser, there were 400 new cases of HIV. To stop the spread of the disease, Bowser set a goal to reduce the number in half by 2020.
to the latest information, there are still some challenges it has to
overcome. The district had 368 new HIV cases for 2017, and the
long-term trend shows a steady drop in the number of new infections.
Kharfen, with D.C. Department of Health, described this as a pause of
many years of continuous drops. However, it does highlight the issue
that what officials are doing is working and must be stepped up
new HIV infections occurred in gay and bisexual men and Latinos with
41 percent of the infections being seen in young people. That’s the
highest amount in 10 years.
2017, 150 people ages 13 to 29 were told they were HIV positive,
which is an increase from 2016’s 134.
city’s health officials are laying out new steps to highlight an
HIV-prevention drug – Pre-exposure prophylaxis. The PrEP pill is
taking daily and can decrease the chances of infection by over 90
were also pushing the drug toward the black women and gay men group,
which are more likely to contract HIV. In 2017, nearly 1,700
residents were given the drug. The FDA recently agreed that the drug,
also called Truvada, could be given to teenagers 15 and older.
the latest school year, the confidential STD screening programs at
area high schools will give students information about the drug.
$300,000 has been set aside to help adolescents pay for the drug.
Although health insurances do cover it, it’s not always easy to
said since most children are under their parents’ insurance plan,
it could be revealing a private part of themselves.
HIV infections have declined, other STDs are increasing.
to the city, there were more than 10,100 cases of chlamydia in 2017 –
a rise of 35 percent since 2013. A 56 percent increase in the number
of cases of gonorrhea, hitting 5,070 cases.
health officials attribute the higher numbers to better screening.
Kharfen said the efforts to get people to use the PrEP drug is
leading to more testing and more positive diagnosis for other STIs.
He said it was time to change how to communicate with young people about their sexual choices but in a positive way.
Here’s what we've been up to recently.
Evofem Bio has launched its Phase 2b/3 clinical trial Amprevence and is accepting enrollees to see how its non-hormonal, on-demand and surfactant-free drug Amphora helps in the prevention of female gonorrhea and urogenital chlamydia.